Zai Lab Q2 FY26 net loss widens to $50.83 million; revenue slips 3% to $106.31 million year over year

ZLAB•2026-08-06

Q2 revenue and loss widen

Zai Lab posted Q2 2026 revenue of USD 106.3 million; net loss widened to USD 50.8 million, or USD 0.46 per ADS.

R&D expenses climbed to USD 61.8 million.
SG&A held roughly flat at USD 72.9 million.

Cash position and product trends

Cash, cash equivalents, short-term investments, and current restricted cash fell to USD 717.5 million as of June 30.

Net product revenue rose 11% versus the prior quarter to USD 105.8 million, driven by ZEJULA stabilization and VYVGART volume growth.

Pipeline and commercialization updates

Pipeline catalysts include zoci combo Phase 1 data slated for ESMO 2026; a registrational Phase 3 start planned in H2 2026; and KarXT launched in mainland China.

Sources

Zai Lab Q2 FY26 net loss widens to $50.83 million; revenue slips 3% to $106.31 million year over year

Publicnow

Zai Lab Q2 FY26 net loss widens to $50.83 million; revenue slips 3% to $106.31 million year over year

Q2 revenue and loss widen

Cash position and product trends

Pipeline and commercialization updates

Related News

Lyell Immunopharma, Inc. <LYEL.O>: Stifel initiates coverage with buy rating; target price $36

Fastly, Inc. <FSLY.O>: Raymond James Raises Target Price to $29 From $23

Lexicon Q2 FY26 net loss widens to $31.8 million; revenue drops to $0.7 million

Sources

Zai Lab Q2 FY26 net loss widens to $50.83 million; revenue slips 3% to $106.31 million year over year

Amylyx Pharmaceuticals Q2 posts higher than expected loss

Abeona Therapeutics schedules conference call on Q2 2026 results